Akebia Therapeutics
245 First Street
Suite 1100
Cambridge
Massachusetts
02142
United States
Tel: 617-871-2098
Website: http://www.akebia.com/
331 articles with Akebia Therapeutics
-
Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting
3/24/2023
Akebia Therapeutics, Inc. announced that it has filed a revised definitive proxy statement with the Securities and Exchange Commission (SEC) in connection with a special meeting (Special Meeting) of stockholders.
-
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
3/9/2023
Akebia Therapeutics®, Inc. today reported financial results for the fourth quarter and full-year ended December 31, 2022 and provided business highlights.
-
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Discuss Recent Business Highlights
3/2/2023
Akebia Therapeutics, Inc. today announced plans to release its financial results for the fourth quarter and full-year ended December 30, 2022 on Thursday, March 9.
-
Akebia Receives Positive CHMP Opinion in Europe for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
2/23/2023
Akebia Therapeutics , Inc. (NASDAQ: AKBA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve Vafseo.
-
Akebia Therapeutics announced another delay Tuesday in a series of setbacks for vadadustat, being developed to treat anemia linked to chronic kidney disease.
-
Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
2/21/2023
Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that the company received a second interim response from the U.S. Food and Drug Administration to its Formal Dispute Resolution Request regarding the Complete Response Letter for vadadustat received in March 2022.
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2023
2/1/2023
Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 18,000 shares of Akebia's common stock on January 31, 2023, as inducements material to such employee entering into employment with Akebia.
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2023
1/3/2023
Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 2,000 shares of Akebia's common stock on December 30, 2022, as an inducement material to such employee entering into employment with Akebia.
-
Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA
12/22/2022
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company received an interim response from the U.S. Food and Drug Administration (FDA) to its Formal Dispute Resolution Request regarding the Complete Response Letter received in March 2022 for vadadustat.
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 02, 2022
12/2/2022
Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 3,000 shares of Akebia's common stock on November 30, 2022, as an inducement material to such employee entering into employment with Akebia.
-
Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
11/22/2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company will participate in the Piper Sandler 34th Annual Healthcare Conference, which takes place November 29-December 1, 2022 in New York City, New York.
-
Akebia Therapeutics has submitted a Formal Dispute Resolution Request with the FDA regarding the rejection of vadadustat in anemia due to chronic kidney disease.
-
Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
11/3/2022
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2022 and provided business highlights.
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 02, 2022
11/2/2022
Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 30,000 shares of Akebia's common stock on October 31, 2022, as inducements material to each such employee entering into employment with Akebia.
-
Akebia Therapeutics to Report Third Quarter Financial Results and Highlight Recent Company Milestones
10/27/2022
Akebia Therapeutics, Inc. today announced plans to release its financial results for the third quarter ended September 30, 2022 on Thursday, November 3, 2022 following the close of financial markets.
-
Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022
10/21/2022
Akebia Therapeutics, Inc. today announced that it will present data at the American Society of Nephrology Kidney Week 2022 ( ASN Kidney Week 2022 ), which will take place in Orlando, November 3-6, 2022.
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2022
10/3/2022
Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 50,000 shares of Akebia's common stock on September 30, 2022, as inducements material to each such employee entering into employment with Akebia.
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 02, 2022
9/2/2022
Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 27,000 shares of Akebia's common stock on August 31, 2022, as inducements material to each such employee entering into employment with Akebia.
-
Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference
9/1/2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference.
-
This week, drugs developed by Neurocrine Biosciences, Akebia, Eliem and Athira all failed to meet expectations in clinical trials.